The Psychedelics & Pain Symposium 2025 highlights past, ongoing, and future investigations into how psychedelics treat chronic pain and related physical conditions, i.e. neurodegenerative, autoimmune, and infection-acquired chronic illness.
The Symposium features top research and patient stories, this year focusing on low back pain, phantom-limb pain, fibromyalgia, CRPS, cluster headache, spinal cord injury, and more. Psychedelics show promise for many conditions where common medications are often ineffective. Researchers frequently share early results, giving attendees advanced insight into efficacy and mechanisms involved in profound pain relief. Patients will share real-world results and protocols for self-treating debilitating conditions, including best practices for safety and efficacy.
A recording will be available for attendees after the event.
Your paid registration supports our collective work. If financially challenged, contact [email protected] for a scholarship.
Sessions & Presenters
Your P&P Symposium Host & Interviewer - Court Wing, Founder REMAP Therapeutics, Research Lead PPA
Policy Panel | State of the States - Eileen Brewer, PPA & Kevin Lenaburg, PPA
Psilocybin for Fibromyalgia - Jacob Aday, PhD, Dr. Julia Bornemann, Dr. Sierra Warren
Psilocybin & Pain - The Fight for Cluster Headache Relief in Canada - John Gilchrist, Therapsil
CRPS Microdosing - Case Study - Lauren Lauth, case study subject
Psilocybin for Parkinson’s Trial - Gisele Fernandes-Osterhold, Psychotherapist, UCSF, Center for Psychedelic Therapies and Research, CIIS, Instituto Alma Viva, Centro Avançado de Medicina Psicodélica
Adjunctive Therapies in Psychedelic Settings: Bodywork, Physiotherapy, & other Manual Therapies - Suz Burroughs, Marin Campbell, PT, DPT, Tess Veuthey MD, PhD, UCSF
Microdosing for Spinal Cord Injury - Case Study - Devon Colbert, case study subject
Psilocybin for IBS - Franklin King, IV, MD, Harvard, Mass Gen
Healthy Volunteers Study - Dr. Jan Ramaekers, JG, Maastricht University, Professor of Psychopharmacology, & Mauro Cavarra, Maastricht University, Psychotherapist
PsiloPain Trial Updates/Results - James Close, PhD(c), Imperial College London
Low Back Pain Study & New Mouse Model Data - Boris Heifets, MD PhD, Heifets Lab, Stanford University
DMT for Cluster Headache - Dr. Emmanuelle Schindler, MD, PhD, Yale University
Mechanical Model in Mice in Classic Experimental Pain Models - Imad Damaj, PhD, VCU
Psilocybin Impact on Micronetworks for Pain Signals - Sophie Rodgers PhD(c), Corder Lab at UPenn
Traumatic Brain Injury & Spinal Cord Injury - Case Study - James Hall, case study subject
Your Instructor
Psychedelics and Pain Association
The work of PPA is to explore psychedelics as tools to alleviate suffering from pain and other physical, and neurological conditions. As the only organization dedicated to integrating psychedelic science with the realities of chronic pain, neurological illness, and somatic suffering, we work to coordinate research; educate patients, facilitators, HCPs, and policymakers; and explore a wider range of adjunctive therapies beyond psychotherapeutic interventions.
REMAP Therapeutics
Exploring and innovating at the intersection of psychedelics, chronic pain, and other physical conditions. REMAP uses neuromodulatory approaches to boost the impact of psychedelics in improving maladaptive conditions that have been non-responsive to standard-of-care treatments. With first-in-industry coursework, symposiums, published research, and direct client interventions, REMAP has been advancing proof-of-concept on multiple fronts.